CD274 and plasma cell myeloma: Monitoring PD-L1 expression in bone marrow for patients receiving ASCT could be employed to identify patients who are at high risk for poor outcomes, requiring additional treatment if these findings are confirmed by other, larger studies. Currently, no clinical trials have been published to demonstrate the efficacy of using PD-L1 inhibitors in treating patients with refractory multiple myeloma.